ATE202145T1 - Nukleinsäure-einbringungssystem - Google Patents

Nukleinsäure-einbringungssystem

Info

Publication number
ATE202145T1
ATE202145T1 AT95937039T AT95937039T ATE202145T1 AT E202145 T1 ATE202145 T1 AT E202145T1 AT 95937039 T AT95937039 T AT 95937039T AT 95937039 T AT95937039 T AT 95937039T AT E202145 T1 ATE202145 T1 AT E202145T1
Authority
AT
Austria
Prior art keywords
nucleic acid
delivery system
acid delivery
transfer system
protein
Prior art date
Application number
AT95937039T
Other languages
English (en)
Inventor
Winfried Wels
Jesus Fominaya
Original Assignee
Winfried Wels
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Winfried Wels filed Critical Winfried Wels
Application granted granted Critical
Publication of ATE202145T1 publication Critical patent/ATE202145T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95937039T 1994-11-01 1995-10-31 Nukleinsäure-einbringungssystem ATE202145T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94810627 1994-11-01
PCT/EP1995/004270 WO1996013599A1 (en) 1994-11-01 1995-10-31 Nucleic acid transfer system

Publications (1)

Publication Number Publication Date
ATE202145T1 true ATE202145T1 (de) 2001-06-15

Family

ID=8218332

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95937039T ATE202145T1 (de) 1994-11-01 1995-10-31 Nukleinsäure-einbringungssystem

Country Status (8)

Country Link
US (1) US6498233B1 (de)
EP (1) EP0789776B1 (de)
JP (1) JPH09511916A (de)
AT (1) ATE202145T1 (de)
AU (1) AU695196B2 (de)
DE (1) DE69521331T2 (de)
NZ (1) NZ295673A (de)
WO (1) WO1996013599A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
DE19649645A1 (de) * 1996-11-29 1998-06-04 Hoechst Ag Mehrfach funktionelles Ligandensystem zur zielzellspezifischen Übertragung von Nukleotidsequenzen
IL130160A0 (en) * 1996-12-02 2000-06-01 Univ Wake Forest Inactivation of HIV co-receptors as therapy for HIV infection
EP0979102A4 (de) 1997-04-30 2005-11-23 Enzon Inc Einzelsträngige polypeptide modifiziert durch polyalkylenoxid
GB9713122D0 (en) * 1997-06-20 1997-08-27 Chiron Spa Novel method of DNA transfer into cells
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
US7314632B1 (en) * 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
DK1000163T3 (da) * 1997-07-11 2006-02-06 Us Gov Health & Human Serv Pseudomonas-exotoksin A-lignende kimære immunogener
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US6903077B1 (en) 1999-01-04 2005-06-07 University Of Vermont And State Agricultural College Methods and products for delivering nucleic acids
FR2793414B1 (fr) * 1999-05-10 2003-05-23 Centre Nat Rech Scient Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
KR100356140B1 (ko) * 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
DE19952957B4 (de) * 1999-11-03 2006-08-31 Acgt Progenomics Ag Modulare Transportsysteme für molekulare Substanzen und deren Herstellung und Verwendung
US20030162733A1 (en) * 2000-11-27 2003-08-28 Haynes Joel R. Nucleic acid adjuvants
US6472176B2 (en) * 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
DE60137969D1 (de) * 2000-12-21 2009-04-23 Us Gov Health & Human Serv Ein chimäres protein das nichttoxische pseudomonas exotoxin a und typ iv pilin sequenzen enthält
US6846484B2 (en) * 2001-12-28 2005-01-25 Regents Of The University Of Minnesota DTAT fusion toxin
EP1592412A1 (de) * 2003-01-31 2005-11-09 Novartis AG Verminderungsregulation der genexpression mit pei/einzelsträngigen oligoribonukleotid-komplexen
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
US7205387B2 (en) * 2003-08-28 2007-04-17 Agency For Science, Technology And Research Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
JP2008505071A (ja) * 2004-07-02 2008-02-21 アヴァリス・アクチエボラーグ 細胞を遺伝学的に活性化する方法、および、該細胞の使用
AU2005294436A1 (en) * 2004-10-04 2006-04-20 Trinity Biosystems, Inc. Methods and compositions for immunizing against Pseudomonas infection
WO2007067597A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
AU2008246928B2 (en) 2007-05-07 2014-04-17 Protalix Ltd. Large scale disposable bioreactor
US7887801B2 (en) * 2007-07-13 2011-02-15 Topotarget Germany Ag Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
WO2011085178A1 (en) * 2010-01-11 2011-07-14 Trustees Of Dartmouth College Monomeric bi-specific fusion protein
PT2525787T (pt) 2010-01-19 2017-12-18 Hanmi Science Co Ltd Formulações líquidas para conjugado de g-csf de longa ação
WO2012038950A1 (en) * 2010-09-20 2012-03-29 Ramot At Tel-Aviv University Ltd. Activatable toxin complexes comprising a cleavable inhibitory peptide
US9095624B2 (en) 2011-05-23 2015-08-04 Contango Partners Group, Inc. Modular transport platform for targeted delivery of therapeutic agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
IL106760A (en) * 1992-08-25 1999-12-31 Miles Inc Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus
DE4339922C1 (de) * 1993-09-03 1994-10-06 Max Planck Gesellschaft Vektor für Leber-Gentherapie
EP0753069A1 (de) * 1994-04-15 1997-01-15 Targeted Genetics Corporation Fusionsprotein für Gentransfer

Also Published As

Publication number Publication date
AU695196B2 (en) 1998-08-06
DE69521331D1 (de) 2001-07-19
US6498233B1 (en) 2002-12-24
AU3926895A (en) 1996-05-23
EP0789776A1 (de) 1997-08-20
DE69521331T2 (de) 2001-09-20
NZ295673A (en) 1999-03-29
WO1996013599A1 (en) 1996-05-09
JPH09511916A (ja) 1997-12-02
EP0789776B1 (de) 2001-06-13

Similar Documents

Publication Publication Date Title
ATE202145T1 (de) Nukleinsäure-einbringungssystem
Fujinaga et al. Identification and characterization of functional subunits of Clostridium botulinum type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes
MX9800719A (es) Proteinas de transporte y sus usos.
WO1999004820A3 (en) Cytolysis of target cells by superantigen conjugates inducing t-cell activation
HRP20030088B1 (hr) Anti-dvostruka integrinska protutijela, pripravci, postupci i primjena
DE69638142D1 (de) Regulierte Gene und ihre Verwendungen
SE9803099D0 (sv) Nucleic acid transfer
DK0941318T3 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
ATE240738T1 (de) Verwendung von epithel-adhärente lactobazillen
NZ524888A (en) Nucleic acids and proteins from streptococcus groups A & B
ATE246516T1 (de) Neue enzyme und prodrugs für adept
CY1106504T1 (el) Υβριδιακες πρωτεϊνες του τοξοειδους του τετανου που μετακινουνται παλινδρομικα και διασυναπτικα στο κνς
ATE261494T1 (de) Konstrukte zur verabreichung von therapeutischen wirkstoffen an die neuronzellen
Hundal et al. Lack of ability of trypsin‐treated mitochondrial F1‐ATPase to bind the oligomycin‐sensitivity conferring protein (OSCP)
AR003407A1 (es) Procedimiento de clonacion de un acido nucleico que codifica una proteina con actividad de delta-5,7-esterol, delta-7-reductasa, procedimiento de preparacion de la proteina, procemiento de reduccion in vitro de un esterol insaturado, procedimiento de produccion de pregnenolona, cepa de levadura transformada y metodo de diagnostico in vitro para la deteccion de la deficiencia de delta-5, 7-esterol, delta-7-reductasa
FR2780062B1 (fr) Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
AU1060397A (en) High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
Rago et al. Staphylococcal exfoliative toxins cleave α-and β-melanocyte-stimulating hormones
DE59611307D1 (de) Nucleinsäure-moleküle codierend proteine, die die adhäsion von neisseria-zellen an humane zellen vermitteln
EP1023906A4 (de) Verstärker für antikörper gegen lymphoiden tumor
AP2003002826A0 (en) Therapeutic agent comprising a B-subunit of a protein toxin
DE69613685D1 (de) D-aminosäure-oxidase kodierendes dns-fragment
AU2256197A (en) High affinity nucleic acid ligands of complement system proteins
Etherington et al. Investigation of the cathepsins of human gastric carcinomata
Roberts et al. The type II secretion system utilizes GspN for transport of lipoproteins to the Acinetobacter baumannii cell surface

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties